immunity News and Research

RSS

Severe symptoms result in high titers of SARS-CoV-2 antibodies

Scientists have focused on determining the cause-effect relationship between SARS-CoV-2 antibody titers and COVID-19 disease severity.

9 May 2022

LJI researchers uncover new drug target for severe asthma, lung fibrosis

If you've ever struggled to breathe, you've had a moment of hypoxia - a lack of oxygen. Hypoxia can have long-term effects. In fact, doctors describe hypoxia as an "initial insult."

9 May 2022

Study identifies interleukin-6 as a potential target in refining cancer therapies

Immune checkpoint inhibitors have revolutionized the treatment of many cancers by using our body's immune system to kill cancer.

9 May 2022

Targeting interleukin-6 could help reduce immune-related adverse events from immunotherapy

Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).

9 May 2022

Third BNT162b2 dose elicits more durable immune response than second dose

Researchers evaluated the durability of immune responses post-third dose of the BNT162b2 vaccine against SARS-CoV-2.

9 May 2022

Comparison of COVID-19 vaccination schemes

Researchers assessed SARS-CoV-2 neutralizing antibodies in Chile.

9 May 2022

COVID-19 booster or additional primary vaccination dose against SARS-CoV-2 Omicron in nursing home occupants

A recent study assessed the efficacy of SARS-CoV-2 primary series vaccination, additional initial dose, or booster shot against the SARS-CoV-2 Omicron infection in the nursing home.

9 May 2022

The potential impact of oral vaccination against COVID-19 on transmission to naïve individuals studied in a hamster infection model

A recent article published in Science Translational Medicine demonstrated that mucosally delivered adenovirus type 5 (Ad5)-based COVID-19 vaccination minimized COVID-19 transmission and severity.

9 May 2022

Effectiveness of BNT162b2 third dose against Omicron-associated severe disease

Researchers analyzed the effectiveness of the SARS-CoV-2 BNT162b2 third vaccine dose against SARS-CoV-2 Omicron-induced severe infection nearly seven months post-vaccination.

9 May 2022

COVID-19 mortality among elderly may be due to genetically predetermined limit on the immune system

Your immune system's ability to combat COVID-19, like any infection, largely depends on its ability to replicate the immune cells effective at destroying the SARS-CoV-2 virus that causes the disease.

9 May 2022

Infection with SARS-CoV-2 results in antibodies against common colds

A study published in the journal Science Advances uses electron microscopy-based polyclonal epitope mapping (EMPEM) methodology to elucidate the spike epitopes of β-HCoV targeted by preexisting serum antibodies and compares them to the epitopes targeted by antibodies elicited by SARS-CoV-2 infection using electron microscopy-based polyclonal epitope mapping (EMPEM) methodology.

8 May 2022

Scientists explore immunopathology of COVID-19

Researchers explored the interactions between severe acute respiratory syndrome coronavirus 2 and the host in the development of COVID-19.

6 May 2022

A guide to help you keep up with the omicron subvariants

Two years into the coronavirus pandemic, Americans can be forgiven if they've lost track of the latest variants circulating nationally and around the world. We've heard of the alpha, beta, gamma, delta, and omicron variants, but a new Greek-letter variant hasn't come onto the scene in almost half a year.

6 May 2022

Is type 1 diabetes likely to rise after the COVID pandemic?

A recent article posted to the journal Diabetes/Metabolism Research and Reviews explored the risk of a type 1 diabetes wave after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

6 May 2022

SARS-CoV-2 variants are not evolving to escape from T cell-mediated immunity

In a recent study posted to the bioRxiv* pre-print server, researchers demonstrated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants did not evolve further to escape from T cell-mediated immunity.

6 May 2022

Variolation - Face masks might reduce COVID-19 severity

In a recent study published in the Journal of the Royal Society Interface, researchers developed an epidemiological model to demonstrate that mask-induced variolation causes milder severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

5 May 2022

Crucial discovery could inform potential strategies to control malaria transmission

WEHI researchers in Melbourne have made a crucial discovery about how asymptomatic malaria infections impact the body, informing potential strategies to control transmission and improve treatment outcomes.

5 May 2022

Discovery provides critical clues to why many immunotherapies trigger dangerous side effects

It's not often that a failed clinical trial leads to a scientific breakthrough. When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.

5 May 2022

Results indicate that Omicron infection induces low levels of neutralizing antibodies in immunocompetent individuals

Researchers assessed the induction of variant-specific neutralizing antibodies against the SARS-CoV-2 spike and nucleocapsid proteins of several SARS-CoV-2 strains.

5 May 2022

Fecal microbiota transplant can reverse hallmarks of aging in mice

In the search for eternal youth, poo transplants may seem like an unlikely way to reverse the aging process.

5 May 2022

immunity News and Research

Severe symptoms result in high titers of SARS-CoV-2 antibodies

LJI researchers uncover new drug target for severe asthma, lung fibrosis

Study identifies interleukin-6 as a potential target in refining cancer therapies

Targeting interleukin-6 could help reduce immune-related adverse events from immunotherapy

Third BNT162b2 dose elicits more durable immune response than second dose

Comparison of COVID-19 vaccination schemes

COVID-19 booster or additional primary vaccination dose against SARS-CoV-2 Omicron in nursing home occupants

The potential impact of oral vaccination against COVID-19 on transmission to naïve individuals studied in a hamster infection model

Effectiveness of BNT162b2 third dose against Omicron-associated severe disease

COVID-19 mortality among elderly may be due to genetically predetermined limit on the immune system

Infection with SARS-CoV-2 results in antibodies against common colds

Scientists explore immunopathology of COVID-19

A guide to help you keep up with the omicron subvariants

Is type 1 diabetes likely to rise after the COVID pandemic?

SARS-CoV-2 variants are not evolving to escape from T cell-mediated immunity

Variolation - Face masks might reduce COVID-19 severity

Crucial discovery could inform potential strategies to control malaria transmission

Discovery provides critical clues to why many immunotherapies trigger dangerous side effects

Results indicate that Omicron infection induces low levels of neutralizing antibodies in immunocompetent individuals

Fecal microbiota transplant can reverse hallmarks of aging in mice

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News